CHARGED ALPHATMFrontier AI stock research

ELV · NYSE

Elevance Health Inc

Healthcare Plans · United States

USD 396.110.4% daily changeQuote 2026-10-06 · USD
Market cap (USD)
US$85.90B
Trailing P/E
17.53x
Forward P/E
13.41x
Quarterly revenue growth
1.4%
Trailing net margin
2.5%
Indicated dividend yield
1.7%

Snapshot 2026-10-06 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.

Next earnings: 2026-10-21 (provider estimate, not issuer-confirmed).

Company background

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.

Company website

Q2 2026

Go beyond the headline.

ELV Stock: Elevance Beat AND Raised Guidance — So Why Did It Fall?

Published 2026-07-16

Comparable businesses

ELV peer comparison

Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.

Comparison stocks

Market metrics · missing or inapplicable values shown as —
MetricELVElevance Health, Inc.Snapshot 2026-10-06Financial period: 2026-06-30CIThe Cigna GroupSnapshot 2026-10-06Financial period: 2026-06-30CVSCVS Health CorporationSnapshot 2026-10-06Financial period: 2026-06-30Peer medianSimilar-size peers only
Market capMarket value, converted to USDUS$85.90BUS$71.82BUS$110.61BUS$91.22Bn=2
Forward P/EProvider forward earnings estimate13.41x8.12x10.13x9.13xn=2
EV / EBITDAEnterprise value / trailing EBITDA9.52x7.57x10.42x9.00xn=2
Revenue growthLatest quarter vs prior-year quarter1.4%6.7%7.1%6.9%n=2
Operating marginLatest reported quarter4.6%4.0%3.9%3.9%n=2
Free cash flow yieldTrailing cash flow / market cap5.0%11.1%7.3%9.2%n=2
Net debt / EBITDANet debt / trailing EBITDA-0.78x1.93x3.74x2.83xn=2
Debt / equityTotal debt / positive book equity0.69x0.74x0.96x0.85xn=2
Trailing P/ETrailing twelve-month earnings17.53x11.24x22.76x17.00xn=2
Price / bookPrice / positive book equity per share1.91x1.68x1.39x1.53xn=2
EV / salesEnterprise value / trailing revenue0.39x0.34x0.42x0.38xn=2
Earnings growthLatest quarter vs prior-year quarter-13.1%10.2%188.8%99.5%n=2
Gross marginTrailing twelve months26.0%9.1%13.6%11.4%n=2
Net marginTrailing twelve months2.5%2.3%1.2%1.7%n=2
Return on equityProvider trailing return; positive equity only11.1%16.8%6.2%11.5%n=2
Free cash flow marginTrailing free cash flow / revenue2.1%2.8%2.0%2.4%n=2
Dividend yieldIndicated annual dividend / price1.7%2.3%3.1%2.7%n=2
Earnings payoutProvider trailing dividend payout30.4%25.4%70.0%47.7%n=2
Current ratioCurrent assets / current liabilities1.52x0.85x0.87x0.86xn=2
BetaProvider historical market sensitivity0.710.300.600.45n=2

Choose a comparison stock

Search covered companies, or search all listed stocks.

Comparison methodology & limitations

Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.

Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.

Reported performance

Financial trends

Reporting period
Financial history
Chart style
Comparison stocks

Financial statements load separately from the research page.

Market context

Valuation & price history

Adjusted closing price

Price history

Price history loads separately.

Earnings-multiple scenario

Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.

Starting assumptions, when available, use provider forward estimates as of 2026-10-06. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.

THE RESEARCH RECORD

Research history for ELV

All available reporting periods
Q2 20262026-07-16
Q1 20262026-04-23
Deep Dive2026-04-22

Reported figures

Verify material figures against company filings. Market data and AI-assisted analysis may contain errors.